Product Name: mTOR (2445-2451) pS2448
Product Number: PE-04BAL00
| Size: | 200 µg | Price: | 8.00 | |
| 1 mg | $US | 16.00 |
Peptide Name: mTOR (2445-2451) pS2448
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the C-terminal fifth of the kinase in the PI3_PI4-kinase domain. S2448 phosphorylation stimulates phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: RTD-pS-YSA
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the C-terminal fifth of the kinase in the PI3_PI4-kinase domain. S2448 phosphorylation stimulates phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: RTD-pS-YSA
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 877.78 Da
Peptide Purity Percent after Synthesis and Purification: >50
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Peptide Purity Percent after Synthesis and Purification: >50
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Scientific Background: mTOR (FRAP1) is a protein-serine/threonine kinase of the Atypical group and PIKK family. It mediates cell growth, metabolism, and survival. It regulates various cellular pathways such as insulin signalling, eIF4e and p70S6 kinase activation for protein synthesis, HIFa, VEGF, nutrient and hormone signals, ribosome biogenesis, regulation of cell cycle progression, angiogenesis, cell polarity and cytokeleton reorganization. Phosphorylation of S2448 and S2481 increases its phosphotransferase activity, and it is stimulated by RHEBm. Phosphorylation of T2446 inhibits phosphorylation of the S2448 activatory site. It is also negatively regulated by DEPDC6. Dysregulation in signalling that leads to constant activation of mTOR lead to uncontrolled proliferation and cell cycle progression and oncogensis. Increased invasiveness has also be shown do be associated with mTOR activity. While it features a wide range of mutations, this might reflect the very large size of the protein rather than its identification as a tumour suppressor protein. Cancer-related mutations for mTOR in human tumours point to a gain of function of the protein kinase, indicating that it might function as an oncoprotein (OP). The active form of the protein kinase normally acts to promote tumour cell proliferation. mTOR has been linked with Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma (SEGA), Lymphangioleiomyomatosis (LAM), Tuberous Sclerosis Complex, Plasmablastic Lymphoma (PBL), Ewing's tumours, and Kidney Angiomyolipoma.
© Kinexus Bioinformatics Corporation 2017